Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-930-7 | CAS number: 60045-26-3
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No specific study has been performed on the absorption/distribution/metabolism/excretion (ADME) of 3-PPB. However, data are currently available from in vivo toxicology studies performed with this substance and analogue substances. Studies on the ADME of analogue substances, benzyl benzoate, benzyl alcohol, phenylethyl alcohol, benzoic acid are also used to support the registration of 3-PPB.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
- Absorption rate - inhalation (%):
- 100
Additional information
All evidences presented in the report attached below ( TK Assessment_3-PPB_20150128_Final) support a rapid absorption, biotransformation, and excretion of these substances in the urine. 3-phenylpropyl benzoate is expected to rapidly hydrolyse into 3-phenylpropanol and benzoic acid in animal tissues and predominantly in the liver. 3-Phenylpropanol may subsequently be oxidised to 3-phenylpropanoic acid (PPA) by the liver ADH and ALD. PPA is then expected to be oxidised via the hepatic beta-oxidation pathway in hepatic mitochondria leading to the formation of benzoyl CoA. Benzoyl CoA then formed from these reactions may be conjugated with glycine and excreted as hippuric acid or may be hydrolysed to yield free benzoic acid which can also then be excreted. Similarly, benzoic acid is metabolised in the liver by conjugation with glycine, resulting in the formation of hippuric acid. Distribution of the parent compound or metabolites is expected to be wide into most major organs but to be transient as evidenced by extent of its metabolism and excretion. It is concluded that, like benzyl benzoate, 3-PPB may be expected to be absorbed and metabolised to more polar substances which do not bioaccumulate but are rapidly excreted mainly via urine .
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
